Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II): ##STR00001##
Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.

Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II): ##STR00001##
Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.

A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.

2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments are disclosed. The compounds are useful as a medicament in treating and/or decreasing the severity and/or progression and/or preventing fibrosis and/or related diseases, or for use as a medicament in treating, decreasing the severity and/or progression of and/or preventing autophagy and/or related diseases, for inhibiting autophagy flux, and for inhibiting cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or related diseases.

2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments are disclosed. The compounds are useful as a medicament in treating and/or decreasing the severity and/or progression and/or preventing fibrosis and/or related diseases, or for use as a medicament in treating, decreasing the severity and/or progression of and/or preventing autophagy and/or related diseases, for inhibiting autophagy flux, and for inhibiting cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or related diseases.

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.

##STR00001##

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.

##STR00001##

Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II):

##STR00001##

Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.

Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II):

##STR00001##

Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.

Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula (I) or formula (II): ##STR00001##
Wherein X, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, Ar.sub.1 and Ar.sub.2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of the formula (I) or formula (II) as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.